Similar articles

• Topical and systemic medications for the treatment of primary Sjögren's syndrome.

  Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, Bosch X, Tzioufas AG. Ramos-Casals M, et al. Nat Rev Rheumatol. 2012 May 1;8(7):399-411. doi: 10.1038/nrrheum.2012.53. Nat Rev Rheumatol. 2012. PMID: 22549247 Review.
• First report of improvement of coeliac disease in a patient with Sjögren's syndrome treated with rituximab.

  Nikiphorou E, Hall FC. Nikiphorou E, et al. Rheumatology (Oxford). 2014 Oct;53(10):1906-7. doi: 10.1093/rheumatology/keu161. Epub 2014 Apr 11. Rheumatology (Oxford). 2014. PMID: 24729401 No abstract available.
• Maintenance of rituximab treatment in a patient with primary Sjögren's syndrome.

  Lehner GF, Brunner-Palka M, Rettenbacher T, Schmidauer R, Herold M. Lehner GF, et al. Rheumatology (Oxford). 2014 Jul;53(7):1349-50. doi: 10.1093/rheumatology/ket458. Epub 2014 Jan 20. Rheumatology (Oxford). 2014. PMID: 24446469 No abstract available.
• [Sjögren's syndrome: a new approach to treatment].

  Rossier V, Bart PA, Spertini F. Rossier V, et al. Rev Med Suisse. 2012 Apr 18;8(337):843-7. Rev Med Suisse. 2012. PMID: 22594008 French.
• Successful treatment of relapsing autoimmune pancreatitis in primary Sjögren's syndrome with rituximab: report of a case and review of the literature.

  Rueda JC, Duarte-Rey C, Casas N. Rueda JC, et al. Rheumatol Int. 2009 Oct;29(12):1481-5. doi: 10.1007/s00296-009-0843-5. Epub 2009 Jan 11. Rheumatol Int. 2009. PMID: 19137434 Review.